Bioblast Announces Effectiveness of Eight to One Reverse Split
March 06, 2019 06:00 ET
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to...
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
February 19, 2019 07:45 ET
|
Bioblast Pharma Ltd.
Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royaltiesSeelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv,...
Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome
February 14, 2019 19:05 ET
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a...
Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance
January 11, 2019 16:05 ET
|
Bioblast Pharma Ltd.
Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced...
Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors
November 19, 2018 16:15 ET
|
Bioblast Pharma Ltd.
Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of...
Bioblast Pharma Ltd. Corporate and Management Update
July 26, 2018 16:15 ET
|
Bioblast Pharma Ltd.
TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization...
Bioblast Pharma Reports Third Quarter 2017 Financial Results
November 02, 2017 07:30 ET
|
Bioblast Pharma Ltd.
TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Announces Effectiveness of Five to One Reverse Split
September 25, 2017 07:00 ET
|
Bioblast Pharma
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a clinical-stage,...
Bioblast Pharma Reports Second Quarter 2017 Financial Results
August 04, 2017 16:15 ET
|
Bioblast Pharma
TEL AVIV, Israel, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities
June 05, 2017 16:15 ET
|
Bioblast Pharma
JSB-Partners Engaged to Lead the Effort Company Receives Regulatory Clearance to Initiate a Phase 2b trial of Trehalose in OPMD patients TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) --...